Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
LSD
Mental health
Microdosing
Psilocybin
Psychedelics
Wellbeing
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
14 03 2023
14 03 2023
Historique:
received:
18
09
2022
accepted:
22
02
2023
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential methods. This research therefore aimed to explore the way that users make sense of microdosing psychedelics, with a particular focus on the experience of any perceived mental health or wellbeing changes. Participants were recruited via websites and online forums. An internet text-based, semi-structured interview was conducted anonymously with 13 participants regarding their experiences of microdosing psychedelic drugs. Interpretive Phenomenological Analysis was used to analyse the transcripts. Three superordinate themes were identified through the interviews: 1) Seeking a solution: Agency and rationale; 2) Microdosers as scientists; 3) Catalysing desirable and beneficial effects. All participants approached microdosing methodically and with purpose. Participants reported that they had experienced beneficial effects of microdosing on their mental health, alongside cognitive, physical and social changes. By microdosing, participants reported that they had supported their own mental health and wellbeing, with microdosing described as a catalyst to achieving their aims in this area. This study provided additional knowledge and understanding of the experience, rationale and personal meaning of the microdosing phenomenon which can be used to inform future investigations in the areas of psychedelic use and mental health.
Sections du résumé
BACKGROUND
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential methods. This research therefore aimed to explore the way that users make sense of microdosing psychedelics, with a particular focus on the experience of any perceived mental health or wellbeing changes.
METHOD
Participants were recruited via websites and online forums. An internet text-based, semi-structured interview was conducted anonymously with 13 participants regarding their experiences of microdosing psychedelic drugs. Interpretive Phenomenological Analysis was used to analyse the transcripts.
RESULTS
Three superordinate themes were identified through the interviews: 1) Seeking a solution: Agency and rationale; 2) Microdosers as scientists; 3) Catalysing desirable and beneficial effects.
CONCLUSIONS
All participants approached microdosing methodically and with purpose. Participants reported that they had experienced beneficial effects of microdosing on their mental health, alongside cognitive, physical and social changes. By microdosing, participants reported that they had supported their own mental health and wellbeing, with microdosing described as a catalyst to achieving their aims in this area. This study provided additional knowledge and understanding of the experience, rationale and personal meaning of the microdosing phenomenon which can be used to inform future investigations in the areas of psychedelic use and mental health.
Identifiants
pubmed: 36918852
doi: 10.1186/s12888-023-04628-9
pii: 10.1186/s12888-023-04628-9
pmc: PMC10012542
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Informations de copyright
© 2023. Crown.
Références
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
Nordisk Alkohol Nark. 2018 Feb;35(1):39-51
pubmed: 32934512
Sci Rep. 2021 Jan 21;11(1):1941
pubmed: 33479342
Nat Rev Neurosci. 2010 Sep;11(9):642-51
pubmed: 20717121
Int J Drug Policy. 2019 Aug;70:33-39
pubmed: 31071597
Am J Public Health. 2015 Aug;105(8):e31-44
pubmed: 26066933
Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434
pubmed: 31152167
Psychopharmacology (Berl). 2019 Feb;236(2):731-740
pubmed: 30604183
J Psychoactive Drugs. 2020 Apr-Jun;52(2):101-112
pubmed: 31648596
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Front Psychiatry. 2019 Sep 13;10:672
pubmed: 31572246
PLoS One. 2019 Feb 6;14(2):e0211023
pubmed: 30726251
Psychopharmacology (Berl). 2019 Apr;236(4):1159-1170
pubmed: 30478716
J Ment Sci. 1954 Apr;100(419):491-507
pubmed: 13175011
Psychopharmacology (Berl). 2018 Dec;235(12):3401-3413
pubmed: 30357434
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113
pubmed: 28443617
BMC Public Health. 2019 Dec 19;19(1):1712
pubmed: 31856772
Biol Psychiatry. 2019 Nov 15;86(10):792-800
pubmed: 31331617
Exp Clin Psychopharmacol. 2000 May;8(2):225-49
pubmed: 10843306
Psychopharmacology (Berl). 2020 May;237(5):1521-1532
pubmed: 32043165
Harm Reduct J. 2019 Jul 10;16(1):43
pubmed: 31288862